Comparative Pharmacology
Head-to-head clinical analysis: LEVONEST versus ZOVIA 1 50E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONEST versus ZOVIA 1 50E 21.
LEVONEST vs ZOVIA 1/50E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.
Combination estrogen-progestin contraceptive: Ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; Norethindrone induces cervical mucus thickening and endometrial thinning, impeding sperm penetration and implantation.
One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets for 28-day cycle.
None Documented
None Documented
The terminal elimination half-life is approximately 24-30 hours. This relatively long half-life supports once-daily dosing and allows for stable plasma concentrations within 5-7 days of continuous use.
Terminal elimination half-life: 13±3 hours (range 10-20 h) for the progestin component; clinical context: steady-state achieved within 5 days, with minimal accumulation.
Renal excretion of conjugated metabolites accounts for approximately 60-80% of an administered dose; fecal elimination via bile accounts for 20-40%.
Renal: ~50% (metabolites); Fecal: ~30% (metabolites); Biliary: minor; Unchanged drug: <1% renal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive